Cutaneous melanoma is the most dangerous and aggressive form of skin cancer, characterised by the transformation and invasive growth of melanocytes 1 . The incidence rate of melanoma is rising worldwide 2-3 .
Introduction
Cutaneous melanoma is the most dangerous and aggressive form of skin cancer, characterised by the transformation and invasive growth of melanocytes 1 . The incidence rate of melanoma is rising worldwide [2] [3] .
Radical excision of the primary tumour is currently the only curative treatment option 4 , however surgery is rarely an option for patients with metastatic disease. The prognostic outlook for metastatic disease is bleak, with two-year overall survival rates of 10% 5 .
Melanoma has poor sensitivity to traditional treatment methods involving chemotherapy and radiation therapy. The human immune system is capable of mounting a cytotoxic response against melanoma 9 , and thus enhancing specific tumour-killing immune responses against melanoma presents as an attractive therapeutic strategy. To date, several melanoma-associated antigens have been identified and the strikingly immunodominant 10 , well characterised melanoma-associated antigen, Melan-A, has generated considerable clinical interest with regards to developing an anti-melanoma vaccine 11 .
As critical regulators of immune responses, DCs are of significant importance in designing rational anti-cancer vaccines [12] [13] . Very little is known about how human skin DCs process cancer antigens to generate tumour killing responses and whether this can be clinically translated to advance cancer therapy. Demonstrating the ability of skin DCs to elicit a cytotoxic anti-melanoma response will facilitate the development of novel anti-melanoma immunotherapies through direct targeting of cross-priming DC subsets.
The aim of this study was to test the ability of human skin APCs to cross-prime naïve CD8 This study shows epidermal LCs are capable of effectively cross-priming naïve CD8 + T cells against Melan-A in vitro. However, the number of donors is not adequate to reach statistical significance and merit LCs with the definitive status of a cross-priming DC subset; further investigation is required in order to consolidate these results. Ultimately, these findings will facilitate the development of novel anti-melanoma immunotherapies, through direct targeting of cross-priming DC subsets.
